Introduction: Benign prostatic hyperplasia (BPH) is a benign neoplasm that develops from the constituent elements of the prostate. It is a common age-related condition, with more than 50% of men over 50 years old exhibiting symptoms indicative of BPH. It is the main cause of lower urinary tract symptoms (LUTS). Materials and Methods: This was a prospective, descriptive and longitudinal study over a six-month period from December 15, 2023, to May 15, 2024. All patients admitted for BPH and who received medication treatment during this period were included in the study. Results: The average age of patients was 65.4 years, with the 60 to 69-year age group being the most represented (37.18%). There was no statistical link between the level of education and the occurrence of erection dysfunction ED. 66.67% of patients suffered from ED before treatment. Age was a major risk factor. 94.87% of patients were treated with Alpha-blockers due to their tolerance and effectiveness. 14.10% of patients had a history of inguinal herniorrhaphy, often due to the strain of urination and physical labor. 46.16% of patients had hypertension. No significant link was found between comorbidities and ED. 38.45% of patients consumed tobacco or alcohol. Tobacco was a significant risk factor for ED. 57.67% of patients suffered from ED after treatment, indicating an improvement compared to 66.67% before treatment. However, 24.36% did not ejaculate during sexual intercourse. Conclusion: Medication treatment is the first-line treatment for BPH. However, it can lead to retrograde ejaculation, negatively impacting ejaculatory function. The results showed that the treatment improves patients’ sexuality (IIEF-5 score), but age and tobacco consumption increase the risk of sexual dysfunction.
References
[1]
Gacci, M., Eardley, I., Giuliano, F., Hatzichristou, D., Kaplan, S.A., Maggi, M., et al. (2011) Critical Analysis of the Relationship between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. EuropeanUrology, 60, 809-825. https://doi.org/10.1016/j.eururo.2011.06.037
[2]
Descazeaud, A., de La Taille, A., Giuliano, F., Desgrandchamps, F. and Doridot, G. (2015) Effets négatifs sur la sexualité des traitements médicamenteux des symptômes du bas appareil urinaire liés a l’hypertrophie bénigne de la prostate. Progrès en Urologie, 25, 115-127. https://doi.org/10.1016/j.purol.2014.12.003
[3]
Descazeaud, A., Robert, G., Delongchamps, N.B., Cornu, J., Saussine, C., Haillot, O., et al. (2012) Bilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie bénigne de prostate: Recommandations du CTMH de l’AFU. Progrès en Urologie, 22, 977-988. https://doi.org/10.1016/j.purol.2012.10.001
[4]
Wessells, H., Roy, J., Bannow, J., Grayhack, J., Matsumoto, A.M., Tenover, L., et al. (2003) Incidence and Severity of Sexual Adverse Experiences in Finasteride and Placebo-Treated Men with Benign Prostatic Hyperplasia. Urology, 61, 579-584. https://doi.org/10.1016/s0090-4295(02)02401-9
[5]
Madersbacher, S., Sampson, N. and Culig, Z. (2019) Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 65, 458-464. https://doi.org/10.1159/000496289
[6]
Calogero, A.E., Burgio, G., Condorelli, R.A., Cannarella, R. and La Vignera, S. (2018) Epidemiology and Risk Factors of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. TheAgingMale, 22, 12-19. https://doi.org/10.1080/13685538.2018.1434772
[7]
Calais Da Silva, F., Marquis, P., Deschaseaux, P., Gineste, J.L., Cauquil, J. and Patrick, D.L. (1997) Relative Importance of Sexuality and Quality of Life in Patients with Prostatic Symptoms: Results of an International Study. EuropeanUrology, 31, 272-280. https://doi.org/10.1159/000474467
[8]
Bearelly, P. and Avellino, G.J. (2021) The Role of Benign Prostatic Hyperplasia Treatments in Ejaculatory Dysfunction. FertilityandSterility, 116, 611-617. https://doi.org/10.1016/j.fertnstert.2021.07.1199
[9]
Clifford, G.M. and Farmer, R.D.T. (2000) Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature. EuropeanUrology, 38, 2-19. https://doi.org/10.1159/000020246
[10]
Pushkar, D.Y.P., Loran, O.B.L. and Bernikov, A.N.B. (2022) The Influence of Alfuzosin Monotherapy on the Sexual Function of Patients with Benign Prostatic Hyperplasia in Real Clinical Practice (Results of a Russian Multicenter Study). Urologiia, 6, 21-29. https://doi.org/10.18565/urology.2022.6.21-29
[11]
Baboudjian, M. and Mallet, R. (2024) Traitement de l’hyperplasie bénigne de la prostate: Souhaits et attentes des patients. Progrès en Urologie—FMC. https://doi.org/10.1016/j.fpurol.2024.04.008
[12]
Montiel-Jarquín, Á.J., Gutiérrez-Quiróz, C.T., Pérez-Vázquez, A.L., Ortiz-Agustín, J.J., García-Galicia, A. and Loría-Castellanos, J. (2021) Quality of Life and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia. Cirugía y Cirujanos, 89, 218-222.
[13]
Khallouk, A., Ahallal, Y., Mellas, S., Fadl Tazi, M., Elfassi, M.J. and Farih, M.H. (2010) La dysfonction érectile associée à une hypertrophie bénigne de prostate (HBP) symptomatique: Son lien avec le stade évolutif de l’HBP, et son évolution sous différentes thérapeutiques. BasicandClinicalAndrology, 20, 262-265. https://doi.org/10.1007/s12610-010-0106-z
[14]
Johannes, C.B., Araujo, A.B., Feldman, H.A., Derby, C.A., Kleinman, K.P. and McKinlay, J.B. (2000) Incidence of Erectile Dysfunction in Men 40 to 69 Years Old: Longitudinal Results from the Massachusetts Male Aging Study. JournalofUrology, 163, 460-463. https://doi.org/10.1016/s0022-5347(05)67900-1
[15]
Rouprêt, M., Seisen, T., De La Taille, A. and Desgrandchamps, F. (2012) Troubles sexuels associés aux maladies de la prostate. Progrès en Urologie, 22, S14-S20. https://doi.org/10.1016/s1166-7087(12)70030-1
[16]
Wisard, M. and Leisinger, H. (2005) Hyperplasie bénigne de la prostate et troubles sexuels. RevueMédicaleSuisse, 1, 2861-2865. https://doi.org/10.53738/revmed.2005.1.44.2861
[17]
Corman, A. (2014) Les troubles urinaires du bas appareil (TUBA) dans la pratique du médecin sexologue: comment mieux prendre en charge nos patients. Sexologies, 23, 134-139. https://doi.org/10.1016/j.sexol.2014.07.003
[18]
Ferretti, L., Robert, G. and De La Taille, A. (2012) Dysfonction érectile et hyperplasie bénigne de la prostate: Deux pathologies fréquentes de l’homme âgé. Progrès en Urologie—FMC, 22, F78-F82. https://doi.org/10.1016/j.fpurol.2012.05.001
[19]
Peyronnet, B., Seisen, T., Phé, V., Misrai, V., de la Taille, A. and Rouprêt, M. (2017) Symptômes du bas appareil urinaire secondaire à une hyperplasie bénigne de prostate et dysfonction érectile: Une revue systématique de la littérature. La Presse Médicale, 46, 145-153. https://doi.org/10.1016/j.lpm.2016.09.002
[20]
Alhamam, A., Garabed, L.R., Julian, S. and Flannigan, R. (2023) The Association of Medications and Supplements with Human Male Reproductive Health: A Systematic Review. FertilityandSterility, 120, 1112-1137. https://doi.org/10.1016/j.fertnstert.2023.10.021
[21]
Wilt, T.J., Ishani, A. and Cochrane Urology Group (1996) Pygeum Africanum for Benign Prostatic Hyperplasia. Cochrane Database of Systematic Reviews, 2011.
[22]
Braun, M.H., Sommer, F., Haupt, G., Mathers, M.J., Reifenrath, B. and Engelmann, U.H. (2003) Lower Urinary Tract Symptoms and Erectile Dysfunction: Co-Morbidity or Typical “Aging Male” Symptoms? Results of the “Cologne Male Survey”. EuropeanUrology, 44, 588-594. https://doi.org/10.1016/s0302-2838(03)00358-0
[23]
Abou-Farha, M., Hagras, A. and Nagla, S. (2024) Effect of Dose Reduction of Dutasteride in Combination with Alpha-Blockers in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Enlargement. UrologyAnnals, 16, 120-124. https://doi.org/10.4103/ua.ua_15_22
[24]
Favilla, V., Russo, G.I., Privitera, S., Castelli, T., Giardina, R., Calogero, A.E., et al. (2016) Impact of Combination Therapy 5-Alpha Reductase Inhibitors (5-ARI) plus Alpha-Blockers (AB) on Erectile Dysfunction and Decrease of Libido in Patients with LUTS/BPH: A Systematic Review with Meta-Analysis. TheAgingMale, 19, 175-181. https://doi.org/10.1080/13685538.2016.1195361
[25]
AUA Practice Guidelines Committee (2003) AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Journal of Urology, 170, 530-547.
